MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Total comprehensiveloss-$80,547,000 (-184.89%↓ Y/Y)Net loss-$79,241,000 (-203.20%↓ Y/Y)Other comprehensive(gain) income-$1,306,000 (38.91%↑ Y/Y)Loss before incometaxes-$78,391,000 (-216.88%↓ Y/Y)Income tax expense$850,000 (-39.16%↓ Y/Y)Foreign currencytranslation adjustment-$580,000 (-190.20%↓ Y/Y)Unrealized (loss) gain onavailable for sale...-$483,000 Reclassification adjustment forrealized net (loss) gain...$243,000 Interest and investmentincome$5,138,000 (-34.88%↓ Y/Y)Loss from operations-$79,773,000 (-159.20%↓ Y/Y)Interest expense$2,731,000 (-5.07%↓ Y/Y)Other non-operatingincome (expense), net-$1,025,000 (-199.90%↓ Y/Y)Research and development$59,891,000 (79.08%↑ Y/Y)General andadministrative$19,882,000 (61.20%↑ Y/Y)
Income Statement
source: myfinsight.com

Centessa Pharmaceuticals plc (CNTA)

Centessa Pharmaceuticals plc (CNTA)